Objective To summarize and analyze the different views on the extent of lymphadenectomy in gastric cancer, and ways or methods to dissolve the disagreements. Methods The reports and advances on lymphadenectomy in gastric carcinomas were collected and reviewed.Results Eastern and western scholars presented different view on lymph nodes dissection in gastric cancers because of the difference in nationalty,studying method and operating technique.Conclusion Although extended lymph node dissection for gastric cancers are supported by more and more reports, it is difficult to evaluate the role exactly. Searchers over the world should learn from each other and explore further in order to develop guiding principles in the end.
ObjectiveTo analyze the status of applying programmed death-1 (PD-1) / programmed death-ligand 1 (PD-L1) inhibitors combined with vascular endothelial growth factor (VEGF) / vascular endothelial growth factor receptor (VEGFR) inhibitors in advanced refractory colorectal cancer. MethodThe relevant literature on domestic and foreign research in recent years was summarized. ResultsThe discovery of immune checkpoint PD-1/PD-L1 and the clinical application of related drugs had changed the treatment pattern of advanced solid tumors, but PD-1/PD-L1 inhibitors had a poor efficacy in the mismatch repair prodicient tumors, and most advanced colorectal cancer belonged to this type. The combination of PD-1/PD-L1 inhibitors and VEGF/VEGFR inhibitors could enhance the therapeutic effect in the advanced refractory colorectal cancer, and their interaction mechanisms and clinical efficacy were continuously being proven. ConclusionsThe combination of PD-1/PD-L1 inhibitors and VEGF/VEGFR inhibitors is a promising treatment strategy for advanced refractory colorectal cancer. More studies need to be further clarified its efficacy.